Aclaris Therapeutics (ACRS) Liabilities and Shareholders Equity (2014 - 2026)

Aclaris Therapeutics' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $198.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.32% year-over-year to $198.7 million; the TTM figure through Mar 2026 stood at $723.9 million (down 4.99% YoY), while the FY2025 annual figure was $160.5 million, down 27.17% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $198.7 million, up from $160.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $278.0 million in Q2 2022, with the low at $160.5 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $198.7 million (2026), against an average of $209.9 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 40.35% in 2022, then slumped 31.65% in 2024.
• Aclaris Therapeutics' Liabilities and Shareholders Equity stood at $254.6 million in 2022, then slipped by 22.46% to $197.4 million in 2023, then gained by 11.61% to $220.3 million in 2024, then slipped by 27.17% to $160.5 million in 2025, then grew by 23.84% to $198.7 million in 2026.
• Business Quant data shows ACRS's Liabilities and Shareholders Equity at $198.7 million in Q1 2026, $160.5 million in Q4 2025, and $175.5 million in Q3 2025.